The European Stroke Organisation welcomes the submission of abstracts for the 8th European Stroke Conference (ESOC) which will be held on 4-6 May 2022 in Lyon, France.
Abstract Submission Guidelines
Abstract Submission Deadline for late-breaking science, young stroke physicians and researchers as well as ongoing trials.
Tuesday, 22 March 2022, 23:59 CET
The abstract submission is now closed.
Abstract Submission Deadline for all topics except late-breaking science
Tuesday, 11 January 2022, 23:59 CET
The abstract submission for all topics except late-breaking science is now closed.
Important please read:
Scientific Abstracts should contain new, scientifically rigorous information that has not been published previously. ESO encourages simultaneous presentation of scientific results at the Conference and publication of research findings in major journals. Presenters of major clinical trials or other major studies should please discuss their presentation and publication plans with the Abstract Committee well in advance so as to optimise the presentation and publication opportunities.
A research study in which one or more human subjects are prospectively assigned randomly to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioural outcomes.
When submitting a trial, please indicate the trial registration number (e.g. clinicaltrials.gov NO)
Ongoing trials topic:
Is only for proposed posters that will describe the design and/or progress of ongoing trials – trials that will not have closed in time to present results at ESOC 2022.
Results of randomized clinical trials or high impact large studies that will complete after this deadline (but in time to release results in a late-breaking session) can be submitted to the late-breaking trials section. It is important to mention why the submitted science is of high impact. This section is open from 21 February 2022 to 22 March 2022.
If you anticipate having a late-breaking trial, you are encouraged to submit a placeholder abstract now to the regular system. This abstract can describe the trial and the analyses that will be available. This will assist the conference committee in reserving a suitable slot on the programme and you can update your abstract with results during the late-breaking submission window.
In order to standardise the abstract layout, we kindly ask you to read the guidelines carefully.
Guidelines for preparation of abstracts
- Abstracts may only be submitted Abstracts submitted by fax or email will not be accepted.
- Authors should indicate their presentation type preference:
- Poster presentation only
- Oral or Poster presentation
Note: “Poster presentation only” implies that your abstract will be considered for poster
The same person may serve as presenting author on up to 5 abstracts.
- The Scientific Programme Committee reserves the right to decide on the final allocation and
- All abstracts should be submitted and presented in clear UK English with accurate grammar and spelling of a quality suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a native English speaker, by a university specific publications office (or other similar facility) or by a copy editor, prior to submission.
- The presenting author of an accepted abstract must register and attend the congress to ensure the publication of abstracts.
- Submission of an abstract acknowledges your acceptance for the abstract to be published in the official conference publications.
- The presenting author is required to ensure that all co-authors are aware of the content of the abstract and agree to its submission, before submitting the abstract.
- If your abstract has been accepted as e-poster presentation, you will be asked to prepare a poster in electronic format (ePoster). Guidelines will follow based on acceptance of your abstract. Presenting authors will present their posters in e-poster sessions during the congress.
- Abstracts that have been previously presented at another international meeting cannot be considered for a plenary session.
- Abstract title – must be in UPPER CASE and limited to 25 words. Please submit symbols as words.
- Abstract text – limited to 250 words including acknowledgements. Please note word count is affected when tables are included.
- Abstracts should clearly state:
Background and aims
- Use only standard abbreviations. Place special or unusual abbreviations in parentheses after the full word the first time it appears. Use generic drug names.
- Use generic names of drugs. The presentation must be balanced and contain no commercial promotional content.
- Images– The maximum file size of each image is 500 KB. The maximum pixel size of the graph/image is 600(w) x 800(h) pixel. You may upload images in JPG, GIF or PNG format.
- Submissions may not contain patient names, hospital ID numbers or other identifying information.
- Disclosure of Conflicts of Interest: Abstract submitters will be required to disclose any conflict of interests in the submission form.
- Please make sure to state your correct e-mail After having submitted your abstract, you will receive a confirmation by e-mail with the following information:
- reference number of your abstract (for correspondence and questions that might arise)
- your personal user code and password.
If you do not receive a confirmation by e-mail please contact email@example.com .
- Should you wish to make corrections to an abstract already submitted or if you wish to submit other abstracts later, you may use your personal access code. This will shorten the submission procedure.
Corrections to abstracts can only be made up to the deadline of 11 January 2022, 23.59h CET.
Each abstract will be reviewed by at least 4 external blinded experts and final selection will be made by the Scientific Programme Committee. Notification of acceptance or rejection of submitted abstracts will be sent to the corresponding authors via email by mid-February 2022. Full instructions concerning preparation and presentation will be included and will be made available on the conference website.
When contacting the abstract team please refer to the name of the congress.
Abstract hotline: +41 61 686 77 22 (Monday – Friday during CET business hours)